Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | APP | P05067 | 5/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.54 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.54 |
| ▸ | F3 | P13726 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421069 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL6674756 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL15611 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL8872489 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL8872231 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL4070152 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL59457 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL30746 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| SCHEMBL2489079 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2APPTDP1GSK3B | |
| Hydrochloric Acid SCHEMBL10437237 | 0.99 | LMNA (0.70) | LMNASMN1; SMN2APPTDP1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3771335-A1 | REPELLENT COMPOSITION | Athenion AG (CH) | 2021-02-03 | — | — | EP | disclosed |
| EP-3771336-A1 | REPELLENT COMPOSITION | Athenion AG (CH) | 2021-02-03 | — | — | EP | disclosed |
| US-9314021-B2 | Formulations containing insect repellent compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140288167-A1 | Formulations Containing Insect Repellent Compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2014-09-25 | — | — | US | disclosed |
| US-8771718-B2 | Formulated tick and insect repellent compositions | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8748477-B2 | Formulations containing insect repellent compounds | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-06-10 | — | — | US | disclosed |
| CN-101442908-A | Formulated tick and insect repellent compositions | DU PONT (US) | 2009-05-27 | — | — | CN | disclosed |
| EP-2040555-A2 | FORMULATED TICK AND INSECT REPELLENT COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007133683-A2 | FORMULATED TICK AND INSECT REPELLENT COMPOSITIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070264297-A1 | Formulated tick and insect repellent compositions | 1,4Group, Inc. | 2007-11-15 | — | — | US | disclosed |
| US-20060223878-A1 | Formulations containing insect repellent compounds | 1,4Group, Inc. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288167-A1 | Formulations Containing Insect Repellent Compounds | CAT, HNMT, MME | LMNA 3157/4885SMN1; SMN2 1636/4885APP 403/4885 |
| US-20060223878-A1 | Formulations containing insect repellent compounds | CAT, HNMT, MME | LMNA 3157/4885SMN1; SMN2 1636/4885APP 403/4885 |
| US-20070264297-A1 | Formulated tick and insect repellent compositions | MME, FNTA, ACHE | LMNA 1412/4885SMN1; SMN2 2231/4885APP 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.